Stacks
Interaction Unknown
No direct co-administration trial for semaglutide and thymosin alpha-1 (Tα1) exists as of 2026. The interaction map is built from each compound's independent pharmacology: semaglutide's GLP-1R–mediated anti-inflammatory signaling and Tα1's TLR-dependent immune priming operate through non-overlapping receptor systems, making a direct pharmacodynamic collision unlikely but formally uncharacterised.